As an alternative to the systemic delivery of immune checkpoint inhibitors, here the authors develop an in vivo gene-edit strategy using a conductive hydrogel-based electroporation system to enable nucleofection of PD1-targeted CRISPR-Cas9 DNAs into lymph node T-cells, resulting in suppression of PD1 expression and promotion of anti-tumor immune responses in preclinical cancer models.
